Intuitive Surgical Stock Analysis! Risks & Upside Potential
1 extracted signal · 1 resolved · 0 still active
The Patient Investor20 Jul 2026, 17:45 UTC
AI-generated source summary
The video discusses the stock ISRG, noting its price has been declining and is currently trading around $345.42. The analysis suggests a bearish outlook, with a target price of $281.0. The failure bound for this bearish prediction is set at $360.0, meaning if the stock price rises above this level, the bearish thesis would be invalidated. The reasoning provided highlights a deceleration in revenue growth and a high P/E ratio of 39, suggesting the stock is overvalued. The analyst uses a valuation model to project future earnings and calculates that a 10% annual return would require the stock to reach $281.0 in five years. The current valuation is considered too high, with a PE ratio of 39. If the PE ratio were to drop to 25, the stock would need to be at $234, implying a significant downside.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
PEPSI STOCK IS CRASHING! Dividend Cut & Upside
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.